CLIAC Reaffirms Quality, Comparability In Waiver Criteria Proposal To HHS
This article was originally published in The Gray Sheet
Executive Summary
Quality control testing requirements should be included in manufacturer instructions for CLIA-waived assays to compensate for the potential inexperience of lab personnel, the Clinical Laboratory Improvement Advisory Committee (CLIAC) is urging HHS
You may also be interested in...
CLIA Waiver Withdrawal Option Likely Will Be Explored By CDC Subcommittee
The possibility of recommending a process whereby CLIA waivers can be withdrawn for certain in vitro diagnostic tests will be examined by a workgroup of CDC's Clinical Laboratory Improvement Advisory Committee
CLIA Waiver Withdrawal Option Likely Will Be Explored By CDC Subcommittee
The possibility of recommending a process whereby CLIA waivers can be withdrawn for certain in vitro diagnostic tests will be examined by a workgroup of CDC's Clinical Laboratory Improvement Advisory Committee
FDA Pulls CLIA Waiver Guidance, CMS To Take Lead Drafting New Criteria
The Centers for Medicare & Medicaid Services will have the authority to make the final call on whether products receive CLIA waiver, according to FDAers.